BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11878805)

  • 1. Development and applications of surface plasmon resonance-based von Willebrand factor-collagen binding assay.
    Saenko E; Kannicht C; Loster K; Sarafanov A; Khrenov A; Kouiavskaia D; Shima M; Ananyeva N; Schwinn H; Gruber G; Josic D
    Anal Biochem; 2002 Mar; 302(2):252-62. PubMed ID: 11878805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
    Neugebauer BM; Goy C; Budek I; Seitz R
    Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I; Farrugia A; Tran E; Anastasius V; Charnock A
    Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.
    Zhukov O; Popov J; Ramos R; Vause C; Ruden S; Sferruzza A; Dlott J; Sahud M
    Haemophilia; 2009 May; 15(3):788-96. PubMed ID: 19298374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S; Carlson M; Hillarp A
    Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of collagen-binding assay for von Willebrand disease].
    Zhou J; Jia YQ; Jiang H; Yang YM; Deng CQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):126-9. PubMed ID: 14981837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of von Willebrand factor to collagen type III: role of specific amino acids in the collagen binding domain of vWF and effects of neighboring domains.
    van der Plas RM; Gomes L; Marquart JA; Vink T; Meijers JC; de Groot PG; Sixma JJ; Huizinga EG
    Thromb Haemost; 2000 Dec; 84(6):1005-11. PubMed ID: 11154106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options.
    Favaloro EJ
    Am J Clin Pathol; 2000 Oct; 114(4):608-18. PubMed ID: 11026108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of von Willebrand factor activity in factor VIII/von Willebrand factor concentrates with the automated von Willebrand factor: activity IL test.
    Mori F; Rossi P; Nardini I; Gambelli D; Farina C
    Blood Coagul Fibrinolysis; 2010 Apr; 21(3):221-8. PubMed ID: 20179578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced high shear platelet adhesion to the vascular media: defective von Willebrand factor binding to the interstitial collagen.
    Komorowic E; McBane RD; Charlesworth J; Fass DN
    Thromb Haemost; 2002 Apr; 87(4):763-70. PubMed ID: 12013023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a collagen-binding activity assay as a screening test for type II von Willebrand disease in dogs.
    Sabino EP; Erb HN; Catalfamo JL
    Am J Vet Res; 2006 Feb; 67(2):242-9. PubMed ID: 16454628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor.
    Foster PA; Fulcher CA; Houghten RA; Zimmerman TS
    Thromb Haemost; 1990 Jun; 63(3):403-6. PubMed ID: 2119526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and follow-up of thrombotic thrombocytopenic purpura by means of von Willebrand factor collagen binding assay.
    Casonato A; Fabris F; Pontara E; Cattini MG; Zocca N; Gallinaro L; Girolami A; Pagnan A
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):296-304. PubMed ID: 16959682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.